Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy

Diabetes Research and Clinical Practice

Volumn 72, Issue 2, 2006, Pages 135-141

  Seki, N ^a   Hashimoto, N ^a,b   Suzuki, Y ^a   Yagui, K ^a   Saito, Y ^a  

^a CHIBA UNIVERSITY   (Japan)

^b ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme gene polymorphism; Angiotensin converting enzyme inhibitor; Diabetic nephropathy; Transforming growth factor

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 33646123309     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.09.015     Document Type: Article

References (41)

1. Parving H.H., Østerby R., and Ritz E. Diabetic nephropathy. In: Brenner B.M., and Levine S. (Eds). The Kidney. sixth ed. (2000), Saunders, Philaderphia, WB 1731-1773
2. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977-986.
3. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837-853.
4. UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ 317 (1998) 703-713.
5. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
6. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329 (1993) 1456-1462
7. Heart Outcomes Prevention Evaluation Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet 355 (2000) 253-259.
8. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345 (2001) 870-878
9. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
10. Seaquist E.R., Goetz F.C., Rich S., and Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N. Engl. J. Med. 320 (1989) 1161-1165
11. Fujisawa T., Ikegami H., Kawaguchi Y., Hamada Y., Ueda H., Shintani M., et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41 (1998) 47-53
12. Tarnow L., Gluud C., and Parving H.H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol. Dial. Transplant. 13 (1998) 1125-1130
13. Staessen J.A., Wang J.G., Ginocchio G., Petrov V., Saavedra A.P., Soubrier F., et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J. Hypertens. 15 (1997) 1579-1592
14. Rigat B., Hubert C., Corvol P., and Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 20 (1992) 1433
15. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
16. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
17. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349 (2003) 1893-1906
18. Penno G., Chaturvedi N., Talmud P.J., Cotroneo P., Manto A., Nannipieri M., et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47 (1998) 1507-1511
19. Selam J.L., Giraud P., and Mirouze J. The point of no-return for the diabetic kidney is beyond clinical proteinuria. Diabet. Med. 1 (1984) 242
20. Bakris G.L., Siomos M., Richardson D., Janssen I., Bolton W.K., Hebert L., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 58 (2000) 2084-2092
21. Apperloo A.J., de Zeeuw D., and de Jong P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 51 (1997) 793-797
22. Biollaz J., Brunner H.R., Gavras I., Waeber B., and Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol. 4 (1982) 966-972
23. Gottlieb S.S., Dickstein K., Fleck E., Kostis J., Levine T.B., LeJemtel T., et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88 (1993) 1602-1609
24. Gansevoort R.T., de Zeeuw D., and de Jong P.E. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney Int. 45 (1994) 861-867
25. Reeves W.B., and Andreoli T.E. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7667-7669
26. Riser B.L., Cortes P., Heilig C., Grondin J., Ladson-Wofford S., Patterson D., et al. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am. J. Pathol. 148 (1996) 1915-1923
27. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., and Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1814-1818
28. Pfeiffer A., Middelberg-Bisping K., Drewes C., and Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care 19 (1996) 1113-1117
29. Sharma K., Ziyadeh F.N., Alzahabi B., McGowan T.A., Kapoor S., Kurnik B.R., et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46 (1997) 854-859
30. Matsubara M., Suzuki M., Fujiwara T., Kikuya M., Metoki H., Michimata M., et al. Angiotensin-converting enzyme I/D polymorphism and hypertension: the Ohasama study. J. Hypertens. 20 (2002) 1121-1126
31. Rudberg S., Rasmussen L.M., Bangstad H.J., and Osterby R. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 23 (2000) 544-548
32. Kuramoto N., Iizuka T., Ito H., Yagui K., Omura M., Nozaki O., et al. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am. J. Kidney. Dis. 33 (1999) 276-281
33. Weigert C., Brodbeck K., Klopfer K., Haring H.U., and Schleicher E.D. Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia. Diabetologia 45 (2002) 890-898
34. Horiuchi M., Akishita M., and Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33 (1999) 613-621
35. Matsubara H., Moriguchi Y., Mori Y., Masaki H., Tsutsumi Y., Shibasaki Y., et al. Transactivation of EGF receptor induced by angiotensin II regulates fibronectin and TGF-beta gene expression via transcriptional and post-transcriptional mechanisms. Mol. Cell. Biochem. 212 (2000) 187-201
36. Shibasaki Y., Matsubara H., Nozawa Y., Mori Y., Masaki H., Kosaki A., et al. Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase. Hypertension 38 (2001) 367-372
37. Schunkert H., Hense H.W., Holmer S.R., Stender M., Perz S., Keil U., et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N. Engl. J. Med. 330 (1994) 1634-1638
38. Marian A.J., Yu Q.T., Workman R., Greve G., and Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342 (1993) 1085-1086
39. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.P., Arveiler D., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359 (1992) 641-644
40. Lindpaintner K., Pfeffer M.A., Kreutz R., Stampfer M.J., Grodstein F., LaMotte F., et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N. Engl. J. Med. 332 (1995) 706-711
41. Hashimoto N., Maeshima Y., Satoh M., Odawara M., Sugiyama H., Kashihara N., et al. Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am. J. Physiol. Renal Physiol. 286 (2004) F516-F525 (Epub. (2003) 28)